Abstract: Objective:To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKIs) in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods:We screened out seven patients who were diag-nosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from2,317 squamous-cell lung cancer patients treat -ed at the Beijing Chest Hospital from January 2010to July 2016. Results:After using EGFR TKIs, the objective response rate was42. 9%, the disease control rate was 100 % , and the median progression- free survival was6. 1 months.Conclusion: EGFR- TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous- cell lung cancer. However, given that only seven cases are pre -sented in this research group, more cases are needed for further research to verify the above conclusion.